ÂÜÀòÂÒÂ×

Mason Yamashita has extensive experience in the field of pharmacovigilance. Mason is currently serving as the Vice President of Pharmacovigilance at Zenas BioPharma since September 2022. Prior to this, they held the same role at Heron Therapeutics, Inc. from April 2021 to August 2022. Before that, Mason worked at Gossamer Bio, where they initially served as the Executive Director of Pharmacovigilance from April 2018 to March 2020 and later became the Vice President of Pharmacovigilance from March 2020 to April 2021. Mason was also the Vice President of Pharmacovigilance at Conatus Pharmaceuticals from June 2015 to April 2018. Earlier in their career, they held various positions such as Executive Director of Clinical Development at Ionis Pharmaceuticals, Inc. from February 2011 to June 2015, Senior Director of Clinical Development at Ambit Biosciences from August 2010 to February 2011, Medical Director of Drug Safety at Biogen Idec from December 2008 to August 2010, and Associate Director of Drug Safety at Biogen Idec from February 2007 to December 2008. Mason's career in the pharmaceutical industry started with Neurocrine Biosciences, where they served as an Associate Medical Director from an unspecified date in 2005 to 2007.

Mason Yamashita completed their education with an MD degree in Medicine from the University of Hawaii John A. Burns School of Medicine. Mason pursued this degree from 1992 to 1996. Prior to that, they achieved a PhD in Physical Chemistry from UCLA, where they studied from 1985 to 1989.